Glob Heart:世界心脏联盟糖尿病患者预防心血管疾病全球路线图:糖尿病要关注“七驾马车”

2019-09-05 xujing 中国循环杂志

2019年欧洲心脏病学会(ESC)发布了世界心脏联盟(WHF)的新路线图,旨在减轻糖尿病患者的全球心血管疾病负担。

2019年欧洲心脏病学会(ESC)发布了世界心脏联盟(WHF)的新路线图,旨在减轻糖尿病患者的全球心血管疾病负担。

糖尿病患者预防血管疾病要做到以下7点:
(1)保持心脏健康饮食;
(2)不抽烟;
(3)控制体重;
(4)降低血压;
(5)控制糖尿病
(6)控制胆固醇
(7)服用心脏保护药物。

快速的城市化、不健康的饮食和久坐的生活方式导致了肥胖和糖尿病的快速增长,据估计全球有4.25亿人患有2型糖尿病,全球每11个人中就有1天患糖尿病。50%的人不知晓他们的患病情况。

令人担忧的是,这种情况在未来几十年将进一步恶化,预计到2045年糖尿病患者总数将增加到6亿以上。

虽然糖尿病是可以治疗的,但即使在血糖水平得到控制的情况下,糖尿病患者患心血管疾病的风险大大增加。

与没有糖尿病患者相比,糖尿病患者患冠心病、中风、心肌梗死和心绞痛的风险要高出两到三倍。84%的≥65岁糖尿病患者死于心脏病和中风。

对于糖尿病患者的管理预防心血管疾病是首要任务,预防策略主要集中在生活方式管理和风险因素干预。

该路线图是世界心脏联盟(WHF)与国际糖尿病联合会(IDF)合作开发的,提出了一个综合性的糖尿病患者护理方法。

目前,在全球实施有效管理心血管疾病和2型糖尿病,存在诸多挑战,包括:

(1)缺乏对糖尿病患者的心血管疾病风险增加的认识;

(2)改变健康生活方式的态度和行为的困难;

(3)医护人员缺乏对临床指南的依从性;

(4)缺乏综合护理方法进行筛查

(5)内分泌科医生与其他学科医生缺乏沟通;

(6)心血管疾病和2型糖尿病的管理临床实践与指南存在差距;

(7)医疗体系不具备应对慢性病的能力;

(8)无法获得治疗糖尿病和心血管疾病的基本药物

针对糖尿病患者中的心血管疾病的预防、诊断和管理,建议从以下几方面入手:

(1)制定和实施以生活方式和风险因素管理为重点的心血管病预防策略;

(2)在血糖异常的高危人群中筛查2型糖尿病合并糖耐量减低。

(3)提高2型糖尿病的诊断率;

(4)治疗2型糖尿病合并心血管疾病患者。

(5)随访心血管疾病合并糖尿病患者,以保持健康生活。

原始出处:
Mitchell S1, Malanda B2, Damasceno A3,et al.A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes.Glob Heart. 2019 Sep;14(3):215-240. doi: 10.1016/j.gheart.2019.07.009.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-06 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-06 zexyw04
  4. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-06 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1357269, encodeId=819e135e269aa, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474807, encodeId=9f7514e4807f9, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496668, encodeId=c5ae14966685f, content=<a href='/topic/show?id=bbd780e4884' target=_blank style='color:#2F92EE;'>#联盟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80748, encryptionId=bbd780e4884, topicName=联盟)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7fc9269968, createdName=zexyw04, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498628, encodeId=128d1498628b5, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563144, encodeId=d0d21563144ab, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Sep 06 23:55:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042674, encodeId=3b4910426e4ad, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 05 11:55:00 CST 2019, time=2019-09-05, status=1, ipAttribution=)]
    2019-09-05 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

中国心血管医生健康促进行动新闻发布会在京召开

    2013年3月31日,世界心脏联盟(WHF)中国心血管医生控烟项目暨中国心血管医生健康促进行动“新闻发布会”、“讲师培训会”在京召开。   该项目为中华医学会十二五科技支撑项目“中国心血管医生健康促进行动”的重要内容,由世界心脏联盟发起、中国控制吸烟协会吸烟与疾病控制专业委员会、中国康复医学会